![]() Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts. and changed its name to Blueprint Medicines Corporation in June 2011. We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. The company was formerly known as Hoyle Pharmaceuticals, Inc. Transformative science, targeted medicines. to discover, develop, and commercialize small molecule therapeutics targeting kinases. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company has agreements with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease and F. In addition, the company is developing treatments that target cancer and rare genetic diseases. Learn more about the performance of BPMC share prices on eToro. The 17 analysts offering 12-month price forecasts for Blueprint Medicines Corp have a median target of 70.00, with a high estimate of. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. Blueprint Medicines Corp is listed on the NASDAQ, where it trades under the stock ticker BPMC. Its lead drug candidates include BLU-285, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V, abnormally active receptor tyrosine kinases for patients with systemic mastocytosis, a disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor and BLU-554, which is in Phase I clinical trials an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |